Apellis Pharmaceuticals Reports First Quarter 2021 Financial Results
April 29, 2021
Marketing application for pegcetacoplan for paroxysmal nocturnal hemoglobinuria (PNH) is under review by the U.S. Food and Drug Administration (FDA) with a PDUFA target action